Ataraxis AI Named to the 2025 CB Insights’ List of the 50 Most Promising Digital Health Startups
Ataraxis AI recognized for achievements in cancer prognosis
NEW YORK, October 20, 2025 – CB Insights today named Ataraxis AI to its seventh annual Digital Health 50, showcasing the 50 most promising private digital health companies in the world.
“The 2025 Digital Health 50 winners are high-momentum companies poised to define the next era of healthcare,” said Ellen Knapp, Principal Analyst at CB Insights. “This year’s cohort is advancing the shift from reactive to proactive care, developing AI solutions tailored to healthcare's unique regulatory environment, and addressing critical sector-wide challenges from care access to provider burnout and workforce shortages.”
The list primarily includes early- and mid-stage startups driving innovation across digital health. The CB Insights research team picked winning companies based on CB Insights datasets, including deal activity, industry partnerships, team strength, investor strength, employee headcount, and proprietary Commercial Maturity and Mosaic scores. The analysis also incorporated insights from Analyst Briefings submitted directly by the startups.
“AI in healthcare is becoming a reality not just in administrative applications, but also in tools that impact the diagnosis and treatment of life-threatening diseases,” said Jan Witowski, CEO and Co-Founder of Ataraxis AI. “At Ataraxis, we are building tools that help physicians select the most optimal cancer treatment. Ataraxis™ Breast RISK, our first AI-native test for breast cancer patients, is already being adopted nationwide. This award is a testament to our team’s rapid progress—from research to real-world deployment—and to our leadership at the forefront of AI precision medicine.”
Quick facts on the 2025 Digital Health 50:
- The 50 winners span categories such as care delivery, revenue cycle management, drug discovery & development, and diagnostics.
- This year's cohort is deploying AI across a wide variety of use cases, with notable adoption of agentic AI, voice AI, and automated provider workflows.
- Collectively raised $2B in equity funding in 2025 YTD (as of 10/14/2025).
- 52% are early-stage companies (seed/angel or Series A funding).
- Established 140+ business relationships since 2024 with industry leaders including Cleveland Clinic, IBM, and Novartis.
About CB Insights
CB Insights is the leader in predictive intelligence on private companies. It delivers instant insights that help you source and analyze private companies, focus on the right markets, and stay ahead of competitors. Our AI agents are powerful because they translate signals into the exact outputs your teams need to move first — defensible, sourced, and board-ready. To learn more, please visit www.cbinsights.com.
About Ataraxis AI
Ataraxis AI is an AI precision medicine company transforming patient outcomes through the power of artificial intelligence. Its flagship platform, Ataraxis™ Breast, leverages digital pathology and clinical data to support personalized treatment decisions for patients with breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.
Contact: press@ataraxis.ai